Metformin Prostate Cancer Adjuvant Trial


This is a Phase II clinical study to determine if Metformin can increase Prostate Specific Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary treatment with radiation, or surgical patients that are at high risk for recurrence based on surgical pathology. Men with confirmed prostate cancer and rising serum PSA levels will receive Metformin and will be monitored for PSA response and disease progression.

Study Start Date

June 2014

Estimated Completion Date

June 2018


  • Drug: Metformin Hydrochloride Extended Release 750mg


  • Urology: Oncology,Prostate
  • Oncology: Renal/Urologic
  • Pharmacy: Drug Trials,Other Drugs

MeSH Terms

  • Metformin Hydrochloride
  • Prostatic Neoplasms

Study ID

Winthrop University Hospital -- 14015



Trial ID


Study Type


Trial Phase

Phase 2

Enrollment Quota



Winthrop University Hospital

Inclusion Criteria

  • Male > 18 years of age
  • Biopsy confirmed adenocarcinoma of the prostate
  • Able to swallow and retain oral medication
  • Hemoglobin A1C <7.0%
  • Able and willing to participate in the full 12 months of the study
  • Able to understand instructions related to study procedures
  • Able to read and write English

Exclusion Criteria

  • Metastatic Prostate Cancer
  • Prostate Specific Antigen Doubling Time < 6 months
  • Prior Chemotherapy, hormonal therapy, oral glucocorticoid therapy, Gonadotropin-releasing hormone analogue therapy
  • Current or previous use of 5?-reductase inhibitors, antiandrogen drugs, metformin, oral or injectable diabetes drug
  • Diagnosis of Type 1 Diabetes Mellitus
  • Known hypersensitivity to metformin
  • any condition associated with increased risk of metformin associated lactic acidosis
  • participation in any investigational or marketed drug trial within 30 days prior to screening or during study period
  • any unstable, serious co-existing medical conditions including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to screening
  • history of megaloblastic anemia
  • abnormal liver function test (total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase or serum creatinine above upper limit of normal)
  • history of other malignancies, with the exception of adequately treated non-melanoma skin cancer, stage 1 melanoma, non-muscle invasive bladder cancer, or other solid tumors curatively treated with no evidence of disease for at least 5 years
  • history or current evidence of substance abuse within 12 months of screening
  • history of any illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the study or post an additional risk to the subject




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Winthrop University Hospital - Mineola, New York 38.5 miles None None None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.